ArticleBMC cardiovascular disorders2026
Prognostic effect of polypharmacy in ambulatory patients with heart failure: a machine learning-based analysis.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManaging heart failure often involves polypharmacy, reflecting the challenge of balancing multiple treatments to achieve the best outcomes for patients. We aimed to investigate the effect of polypharmacy on survival in ambulatory patients with heart failure and identify key predictors of survival.
methodsWe conducted a secondary analysis of data from 1375 ambulatory patients with heart failure managed at a heart failure clinic in Spain between 2006 and 2016. Patients were stratified into low polypharmacy (< 5 cardiovascular medications) and high polypharmacy groups (≥ 5 cardiovascular medications). Survival was evaluated using Kaplan-Meier curves, log-rank tests, and a multivariable random forest Cox regression model adjusting for demographic and clinical confounders using propensity scores.
resultsThere was a significant relationship between the number of medications used and survival (log-rank test, P = 0.017) with the most pronounced risk observed in those with seven or more medications. Additionally, patients in the high polypharmacy group showed significantly reduced survival probabilities than those in the low polypharmacy group (P = 0.016). The top important predictors of survival were age, N-terminal pro B-type natriuretic peptide, New York Heart Association functional class, heart failure duration, sacubitril-valsartan, β-blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (all P < 0.001). Multivariable analysis (C-index = 0.804) showed that high polypharmacy was independently associated with reduced survival (P < 0.001).
conclusionsHigh polypharmacy is associated with reduced long-term survival in patients with heart failure. This highlights the need for personalized prescribing strategies to minimize the risks associated with polypharmacy while maximizing therapeutic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.